Atlas Trials

Evaluating the Safety and Efficacy of AD17002 Intranasal Spray in Treating Participants With Mild to Moderate COVID-19

Clinical trial NCT05541510 · TERMINATED

Trial details

NCT number
NCT05541510
Sponsor
Advagene Biopharma Co. Ltd.
Status
TERMINATED
Phase
Phase 2, Phase 3
Study type
INTERVENTIONAL
COVID-19
Start date
2022-12-01
Primary completion
2024-08-05
Enrollment
180

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.